Unity Biotechnology earnings were -$27.5M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest UBX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$7.3M, down 13.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, UBX reported annual earnings of -$26.0M, with -34.8% growth.
Unity Biotechnology Earnings Reports & History FAQ
What were Unity Biotechnology's earnings last quarter?
On UBX's earnings call on Invalid Date, Unity Biotechnology (NASDAQ: UBX) reported Q1 2025 earnings per share (EPS) of -$0.43, up 26.47% year over year. Total UBX earnings for the quarter were -$7.30 million. In the same quarter last year, Unity Biotechnology's earnings per share (EPS) was -$0.34.
Is Unity Biotechnology profitable or losing money?
As of the last Unity Biotechnology earnings report, Unity Biotechnology is currently losing money. Unity Biotechnology's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$27.50 million, a 31.87% decrease year over year.
What was UBX's earnings growth in the past year?
As of Unity Biotechnology's earnings date in Invalid Date, Unity Biotechnology's earnings has grown year over year. UBX earnings in the past year totalled -$27.50 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.